XML 64 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]            
Goodwill, gross $ 413,700,000     $ 413,700,000   $ 413,700,000
Change in goodwill allocation, description       Effective in the first quarter of 2020, the Company (i) reorganized its commercial operations and moved responsibility for and reporting of RAYOS to the inflammation segment and (ii) renamed the orphan and rheumatology segment the orphan segment.  This resulted in a $3.2 million increase in the Company’s allocation of goodwill to its inflammation segment and a corresponding decrease in the goodwill allocated to the orphan segment in the first quarter of 2020.    
Accumulated goodwill impairment losses 0     $ 0    
Amortization expense of developed technology $ 66,749,000   $ 57,683,000 125,324,000 $ 115,100,000  
Inflammation [Member]            
Finite-Lived Intangible Assets [Line Items]            
Increase (decrease) in allocation of goodwill   $ 3,200,000        
Orphan [Member]            
Finite-Lived Intangible Assets [Line Items]            
Increase (decrease) in allocation of goodwill   $ (3,200,000)        
Developed Technology [Member] | TEPEZZA [Member]            
Finite-Lived Intangible Assets [Line Items]            
Capitalized payments of intangible assets       $ 313,900,000    
Disposal Group, Not Discontinued Operations [Member] | MIGERGOT Transaction [Member] | Developed Technology [Member]            
Finite-Lived Intangible Assets [Line Items]            
Write off in net book value           $ 17,000,000.0